A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes

0.50 hr(s) | ABIM , CME , MOC , Royal College of Physicians and Surgeons of Canada

Specialty: Myelofibrosis

Therapeutic Area(s): Oncology

Release Date: August 25, 2021

Expiration Date: August 24, 2022

Location: Internet Activity Enduring

In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.

Access this activity